Gestational Trophoblastic Disease Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The gestational trophoblastic disease market size has grown strongly in recent years. It will grow from $2.06 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to public health initiatives, improved understanding of disease pathology, medical research and clinical trials, development of targeted therapies, shift in treatment protocols.

The gestational trophoblastic disease market size is expected to see steady growth in the next few years. It will grow to $2.64 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to healthcare infrastructure development, enhanced telemedicine and remote care, patient-centric care approaches, regulatory approvals for novel treatments, genomic and molecular studies. Major trends in the forecast period include shift towards personalized medicine, advancements in molecular diagnostics, focus on immunotherapies and targeted therapies, integration of digital health technologies, rising awareness and education programs.

The anticipated rise in abnormal pregnancies is expected to fuel the growth of the gestational trophoblastic disease market in the future. Abnormal pregnancies are those that deviate from the normal or expected trajectory and can pose risks to the health of both the mother and the fetus. In cases of abnormal pregnancies, such as molar pregnancies, the trophoblast forms a tumor instead of developing into a fetus, leading to gestational trophoblastic disease. For example, in May 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2022, there were 251,377 abortions among women residing in England and Wales - the highest number since the introduction of the Abortion Act, representing a 17% increase from the previous year. Thus, the increase in abnormal pregnancies is driving the growth of the gestational trophoblastic disease market.

The anticipated rise in cigarette smoking is expected to drive the growth of the gestational trophoblastic disease market in the future. Cigarette smoking involves burning tobacco and inhaling the resulting smoke, which contains a range of harmful chemicals and toxins that can negatively impact various body systems. This practice may damage the DNA of trophoblastic cells, which are crucial for forming the placenta, potentially leading to abnormal cell growth and division, and resulting in gestational trophoblastic disease. For instance, in May 2022, the Australian Bureau of Statistics, a government agency in Australia, reported that the rate of daily smokers increased with age, reaching a peak of 13.6% in the 55-64 age group during the 2021-2022 period. Therefore, the increasing prevalence of cigarette smoking is contributing to the growth of the gestational trophoblastic disease market.

Major companies operating in the gestational trophoblastic disease market are introducing updated guidelines to enhance services. For instance, in May 2022, The Health Service Executive National Cancer Control Programme in Ireland launched an updated gestational trophoblastic disease guideline, aiming to provide comprehensive insights into diagnostic and management strategies. By reducing practice variation and improving the quality of care, these guidelines contribute to better outcomes for gestational trophoblastic disease patients.

Companies in the gestational trophoblastic disease market are innovating treatments, such as reproductive tissue preservation solutions, to offer reliable services. Reproductive tissue preservation solutions, preserving the viability of reproductive tissue, provide flexibility and control over family-building choices. For instance, in June 2022, Inception Fertility introduced HavenCryo, a long-term reproductive tissue and cryopreservation storage solution, allowing indefinite storage of eggs, sperm, and embryos. This solution proves beneficial for individuals diagnosed with gestational trophoblastic disease who need fertility preservation before undergoing treatments that may impact fertility.

Major companies operating in the gestational trophoblastic disease market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Mylan N.V, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Perrigo Company PLC, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., Wockhardt Ltd., Natco Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Arog Pharmaceuticals Inc., Advenchen Laboratories LLC., Mendus AB, AB Science S.A.

Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2022, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gestational trophoblastic disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gestational trophoblastic disease market consists of revenues earned by entities by providing services such as gynecology services, oncology services, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational trophoblastic disease market also includes sales of medications, diagnostic tools, laboratory tests, methotrexate, etoposide, cyclophosphamide, and vincristine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Gestational trophoblastic disease (GTD) encompasses a group of rare and abnormal conditions arising from the anomalous growth of trophoblastic cells, leading to the formation of a tumor within the uterus following conception. The treatment for GTD typically involves uterine evacuation and the ongoing monitoring of human chorionic gonadotropin (hCG) levels.

The main types of gestational trophoblastic disease include hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others. A hydatidiform mole, also referred to as a molar pregnancy, is an uncommon and abnormal pregnancy condition. Treatment options for this condition include surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy. These treatments are administered by various end-users such as hospitals, clinics, diagnostic centers, and others.

The gestational trophoblastic disease market research report is one of a series of new reports that provides gestational trophoblastic disease market statistics, including gestational trophoblastic disease industry global market size, regional shares, competitors with a gestational trophoblastic disease market share, detailed gestational trophoblastic disease market segments, market trends and opportunities, and any further data you may need to thrive in the gestational trophoblastic disease industry. This gestational trophoblastic disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.